Literature DB >> 10190407

Placebo effect of pacemaker implantation in obstructive hypertrophic cardiomyopathy. PIC Study Group. Pacing In Cardiomyopathy.

C Linde1, F Gadler, L Kappenberger, L Rydén.   

Abstract

This study evaluated a possible placebo effect by pacemaker implantation. The study design was a 3-month multicenter, double-blind, randomized cross-over study to compare the effects of atrioventricular (AV) synchronous pacing with an optimal AV delay to inactive pacing in patients with obstructive hypertrophic cardiomyopathy (HC). Quality of life and left ventricular (LV) outflow tract obstruction were evaluated after the first study period in 40 patients assigned to inactive pacing. Data were compared with the corresponding results among the 41 subjects assigned to a first study period of active pacing. During inactive pacing, there was a significant improvement in perceived chest pain, dyspnea, and palpitations. Moreover, LV outflow tract gradient decreased from 71 +/- 32 mm Hg to 52 +/- 34 mm Hg (p = 0.04). In patients assigned to active pacing the reduction of the gradient was significantly more pronounced (70 +/- 24 mm Hg to 33 +/- 27 mm Hg; p <0.0001). The difference in gradient reduction between the groups was highly significant (p <0.00001). In the group assigned to active pacing there was also significant improvement in perceived symptoms as well as in alertness, the ability to be self-autonomous, and strenuous physical exercise. The improvements in the latter were significantly greater in those paced actively compared with patients paced inactively, whereas the changes in perceived symptoms did not differ between groups. In conclusion, pacemaker implantation had a placebo effect on objective and subjective parameters in this group of patients with obstructive HC.

Entities:  

Mesh:

Year:  1999        PMID: 10190407     DOI: 10.1016/s0002-9149(98)01065-0

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  23 in total

Review 1.  Permanent pacing: new indications.

Authors:  M R Gold
Journal:  Heart       Date:  2001-09       Impact factor: 5.994

Review 2.  Analysis of dual-chamber pacing as a treatment for refractory limiting symptoms in patients with obstructive hypertrophic cardiomyopathy.

Authors:  B J Maron
Journal:  Curr Cardiol Rep       Date:  2000-03       Impact factor: 2.931

Review 3.  Hypertrophic cardiomyopathy in childhood.

Authors:  Steven D Colan
Journal:  Heart Fail Clin       Date:  2010-10       Impact factor: 3.179

4.  Unpacking the effects of acupuncture.

Authors:  Liana Fraenkel
Journal:  Arthritis Care Res (Hoboken)       Date:  2010-09       Impact factor: 4.794

Review 5.  Pacing for drug-refractory or drug-intolerant hypertrophic cardiomyopathy.

Authors:  Mohammed Qintar; Abdulrahman Morad; Hazem Alhawasli; Khaled Shorbaji; Belal Firwana; Adib Essali; Waleed Kadro
Journal:  Cochrane Database Syst Rev       Date:  2012-05-16

6.  Debate on the use of arthroscopic surgery for osteoarthritis of the knee.

Authors:  Robert W Jackson
Journal:  Proc (Bayl Univ Med Cent)       Date:  2003-01

7.  Rationale and design of the TRICHAMPION trial: Triple Chamber Pacing in Hypertrophic Obstructive Cardiomyopathy Patients.

Authors:  Antonio Berruezo; Markus Linhart; Angelo Auricchio; José Luis Zamorano; Pilar Santamaria; Roger Borràs; Felip Burgos; Josep Brugada
Journal:  J Interv Card Electrophysiol       Date:  2018-02-03       Impact factor: 1.900

Review 8.  Management of hypertrophic cardiomyopathy in children.

Authors:  Hubert Seggewiss; Angelos Rigopoulos
Journal:  Paediatr Drugs       Date:  2003       Impact factor: 3.022

9.  Cardiac Resynchronization Therapy for Advanced Heart Failure.

Authors:  Philip B. Adamson; William T. Abraham
Journal:  Curr Treat Options Cardiovasc Med       Date:  2003-08

10.  Surgical management of hypertrophic cardiomyopathy in 2007: what is new?

Authors:  Morgan L Brown; Hartzell V Schaff
Journal:  World J Surg       Date:  2008-03       Impact factor: 3.352

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.